G1 Therapeutics Inc (NASDAQ:GTHX) – Wedbush lowered their Q2 2019 EPS estimates for G1 Therapeutics in a note issued to investors on Tuesday, May 14th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings per share of ($0.67) for the quarter, down from their prior forecast of ($0.66). Wedbush currently has a “Outperform” rating and a $67.00 target price on the stock. Wedbush also issued estimates for G1 Therapeutics’ Q3 2019 earnings at ($0.71) EPS, Q4 2019 earnings at ($0.75) EPS, FY2019 earnings at ($2.76) EPS, FY2020 earnings at ($3.26) EPS, FY2021 earnings at ($2.10) EPS, FY2022 earnings at $0.05 EPS and FY2023 earnings at $7.76 EPS.
Several other brokerages also recently weighed in on GTHX. Cowen reaffirmed a “buy” rating on shares of G1 Therapeutics in a research note on Wednesday, March 6th. BidaskClub raised shares of G1 Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, March 30th. Finally, Zacks Investment Research raised shares of G1 Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, March 28th. Two analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $60.43.
Shares of GTHX opened at $22.61 on Friday. G1 Therapeutics has a fifty-two week low of $13.87 and a fifty-two week high of $69.57. The company has a market cap of $890.59 million, a P/E ratio of -8.83 and a beta of 2.50.
G1 Therapeutics (NASDAQ:GTHX) last announced its earnings results on Thursday, May 9th. The company reported ($0.64) earnings per share for the quarter, topping the consensus estimate of ($0.69) by $0.05.
Several large investors have recently made changes to their positions in GTHX. Hillhouse Capital Advisors Ltd. purchased a new position in shares of G1 Therapeutics in the 4th quarter valued at about $18,182,000. Wellington Management Group LLP boosted its stake in shares of G1 Therapeutics by 23.0% during the 1st quarter. Wellington Management Group LLP now owns 4,636,474 shares of the company’s stock worth $76,966,000 after purchasing an additional 866,859 shares during the last quarter. Vanguard Group Inc boosted its stake in shares of G1 Therapeutics by 76.3% during the 3rd quarter. Vanguard Group Inc now owns 1,717,733 shares of the company’s stock worth $89,821,000 after purchasing an additional 743,596 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of G1 Therapeutics by 76.3% during the 3rd quarter. Vanguard Group Inc. now owns 1,717,733 shares of the company’s stock worth $89,821,000 after purchasing an additional 743,596 shares during the last quarter. Finally, FMR LLC boosted its stake in shares of G1 Therapeutics by 6.9% during the 4th quarter. FMR LLC now owns 5,577,754 shares of the company’s stock worth $106,814,000 after purchasing an additional 361,091 shares during the last quarter. 73.47% of the stock is currently owned by institutional investors.
G1 Therapeutics Company Profile
G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase Ib/II clinical trials for patients with extensive-stage small cell lung cancer, as well as Phase II clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase Ib/IIa clinical trials for the treatment of breast cancer and in Phase Ib/II clinical trial for non-small cell lung cancer; and G1T48, an oral selective estrogen receptor degrader, which is in Phase I clinical trial.
Further Reading: Oversold
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.